ロード中...
Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
BACKGROUND: Liraglutide was first released in Japan as a long-acting once-daily glucagon-like peptide-1 receptor agonist. The maximum dose in Japan is 0.9 mg/day, which is half of that used in the United States and the European Union (1.8 mg/day). The efficacy of this maximum allowable dose of lirag...
保存先:
| 出版年: | J Clin Med Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elmer Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4522987/ https://ncbi.nlm.nih.gov/pubmed/26251684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2237w |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|